SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Science gains on acquiring Suven Pharmaceuticals

06 Feb 2019 Evaluate

Suven Life Sciences is currently trading at Rs. 206.10, up by 0.55 points or 0.27% from its previous closing of Rs. 205.55 on the BSE.

The scrip opened at Rs. 202.40 and has touched a high and low of Rs. 211.45 and Rs. 202.40 respectively. So far 28877 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 337.70 on 11-Sep-2018 and a 52 week low of Rs. 163.30 on 23-Mar-2018.

Last one week high and low of the scrip stood at Rs. 211.45 and Rs. 188.40 respectively. The current market cap of the company is Rs. 2616.29 crore.

The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 8.48% and 31.52% respectively.

Suven Life Science has acquired all the shares of Suven Pharmaceuticals (SPL), a public limited company, from its existing shareholders. Pursuant to which, Suven Pharmaceuticals has become a wholly owned subsidiary of the company. The board of directors at their meetings held on February 5, 2019 approved the same. The Board also approved draft Scheme of Arrangement to be filed at the National Company Law Tribunal bench at Hyderabad, for necessary approvals.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×